In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...

Immatics (IMTX) stock is a speculative Buy: anzu-cel 2L melanoma progress, PRAME/IMA402 upside, mid-2026 SUPRAME catalyst and ...

The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center ...

Northrop Grumman (NOC), [RTX (RTX)](https ...

The Cambridge company cut 34% of its workforce in November after its only clinical-stage drug failed. Now it has financing to reach clinical data for preclinical assets. Women unite! Join us for ...

King of Prussia-based Universal Health Services is looking to expand its access to address the growing demand for behavioral health care.

By HealthDay Staff HealthDay ReporterMONDAY, March 9, 2026 (HealthDay News) — Dr. Vinay Prasad, who leads the U.S. Food and ...

Vinay Prasad will leave FDA CBER by end of April, returning to UCSF after a one-year sabbatical, following a prior departure ...

Scientist Vinay Prasad, who oversees the approval process for vaccines and new therapies, is stepping down amid controversies over his decisions to tighten certain regulations. His departure for the ...

UniQure's stock (QURE) closed 26% higher on Monday. Late Friday, the FDA told the Wall Street Journal that Vinay Prasad plans to leave the agency next month. He is the director of the FDA's Center for ...

The administration had cut crucial funding for mRNA-based therapies. The rest of the world might step in and benefit.